CA3145459C - Composition pharmaceutique de darolutamide - Google Patents

Composition pharmaceutique de darolutamide

Info

Publication number
CA3145459C
CA3145459C CA3145459A CA3145459A CA3145459C CA 3145459 C CA3145459 C CA 3145459C CA 3145459 A CA3145459 A CA 3145459A CA 3145459 A CA3145459 A CA 3145459A CA 3145459 C CA3145459 C CA 3145459C
Authority
CA
Canada
Prior art keywords
composition
per weight
pharmaceutical composition
darolutamide
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3145459A
Other languages
English (en)
Other versions
CA3145459A1 (fr
Inventor
Susanna ILMONEN
Juha LINTUNEN
Petteri LYYTINEN
Marko Saalasti
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Priority claimed from PCT/FI2020/050478 external-priority patent/WO2021001603A1/fr
Publication of CA3145459A1 publication Critical patent/CA3145459A1/fr
Application granted granted Critical
Publication of CA3145459C publication Critical patent/CA3145459C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne une composition pharmaceutique pour administration orale, en particulier sous la forme d'un comprimé, comprenant du darolutamide ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif. Le darolutamide est un modulateur puissant du récepteur des androgènes (AR) utile dans le traitement du cancer, en particulier du cancer dépendant de l'AR tel que le cancer de la prostate, et d'autres maladies dans lesquelles l'antagonisme AR est souhaité.
CA3145459A 2019-07-02 2020-07-02 Composition pharmaceutique de darolutamide Active CA3145459C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20195601 2019-07-02
FI20195601 2019-07-02
PCT/FI2020/050478 WO2021001603A1 (fr) 2019-07-02 2020-07-02 Composition pharmaceutique de darolutamide

Publications (2)

Publication Number Publication Date
CA3145459A1 CA3145459A1 (fr) 2021-01-07
CA3145459C true CA3145459C (fr) 2026-04-28

Family

ID=

Similar Documents

Publication Publication Date Title
JP5752227B2 (ja) 口腔内崩壊錠
JP2020502171A (ja) オラパリブの経口徐放性医薬組成物及びその使用
US20070059365A1 (en) Novel formulation of ropinirole
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
MX2014007331A (es) Sistema de multiunidades de granulos de liberacion inmediata.
AU2019232937B2 (en) Ceritinib formulation
US12611397B1 (en) Pharmaceutical composition of darolutamide
JP2012515757A (ja) トリメタジジンの放出調節固形薬剤組成物及びその製造方法
CA2781826A1 (fr) Compositions pharmaceutiques a liberation controlee de galantamine
CA3145459C (fr) Composition pharmaceutique de darolutamide
TWI870615B (zh) 用於治療或預防高血壓和高血脂症之單一劑型的藥學組成物
JP2022540170A (ja) 医薬調製物
HK40068856A (en) Pharmaceutical composition of darolutamide
TWI878600B (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
WO2023036980A1 (fr) Composition pharmaceutique d'acide bempédoïque
TW202500156A (zh) 包含具有ｇ１２ｃ突變的ｋ－ｒａｓ蛋白之抑制劑的固體調配物及製備方法
HK40068369A (en) Pharmaceutical preparation
HK1239565A1 (en) Extended release tablet of cyclobenzaprine
EA041427B1 (ru) Фармацевтические лекарственные формы